KRAS阻害剤市場レポート：2030年までの動向、予測、競合分析

KRAS阻害剤の動向と予測

世界のKRAS阻害剤市場は、2024年から2030年にかけて32.5%のCAGRで成長すると予想されています。この市場の主な促進要因は、ささまざまな種類のがんにおけるKRAS変異の有病率の増加、進行中の臨床試験の数の急増、精密医療と個別化されたがん治療への投資の増加です。世界のKRAS阻害剤市場の将来は、臨床研究室、がん診断センター、病院、がん調査機関、学術機関市場での機会があり、有望に見えます。

KRAS阻害剤市場洞察

Lucintelは、肺がん患者におけるKRW変異の有病率の急増と肺がん治療の調査への注目の高まりにより、肺がんが予測期間中に最も高い成長を遂げると予測しています。

この市場では、臨床調査調査の増加に加え、調査機関とバイオテクノロジー企業とのパートナーシップの拡大により、がん研究機関が引き続き最大のセグメントとなると思われます。

がんの罹患率が高く、主要企業がこの地域に存在するため、北米は予測期間を通じて最大の地域であり続けると思われます。

よくある質問

Q1.市場の成長予測は：

A1.世界のKRAS阻害剤市場は、2024年から2030年にかけて32.5%のCAGRで成長すると予想されています。

Q2.市場の成長に影響を与える主な促進要因は：

A2.この市場の主な促進要因は、さまざまな種類のがんにおけるKRAS変異の有病率の増加、進行中の臨床試験の数の急増、精密医療と個別化されたがん治療への投資の増加です。

Q3.市場の主要セグメントは：

A3.世界のKRAS阻害剤市場の将来は、臨床研究室、がん診断センター、病院、がん調査機関、学術機関市場での機会があり、有望に見えます。

Q4.市場の主要企業は：

A4.主要なKRAS阻害剤企業の一部は次のとおりです。

• Amgen
• Boehringer Ingelheim
• Bridgebio Pharma
• Erasca
• Innovent Biologics
• Incyte
• Mirati Therapeutics
• Novartis
• Jemincare
• Cardiff Oncology

Q5.今後、最大となる市場セグメントは：

A5.Lucintelは、肺がん患者におけるKRW変異の有病率の急増と肺がん治療の調査への注目の高まりにより、肺がんが予測期間中に最も高い成長を遂げると予測しています。

Q6.市場において、今後5年間に最大になると予想される地域は：

回答：北米は、がんの罹患率が高く、主要企業がこの地域に存在するため、予測期間を通じて最大の地域であり続けるでしょう。

Q7.レポートのカスタマイズは可能か：

A6.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界のKRAS阻害剤市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界のKRAS阻害剤市場動向（2018～2023年）と予測（2024～2030年）
• がんの種類別の世界のKRAS阻害剤市場
  • 肺がん
  • 膵臓がん
  • 結腸直腸がん
  • その他
• 最終用途別の世界のKRAS阻害剤市場
  • 臨床研究室
  • がん診断センター
  • 病院
  • がん調査機関
  • 学術機関
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界のKRAS阻害剤市場
• 北米のKRAS阻害剤市場
• 欧州のKRAS阻害剤市場
• アジア太平洋のKRAS阻害剤市場
• その他地域のKRAS阻害剤市場

第5章 競合の分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • がんの種類別の世界のKRAS阻害剤市場の成長機会
  • 最終用途別の世界のKRAS阻害剤市場の成長機会
  • 地域別の世界のKRAS阻害剤市場の成長機会
• 世界のKRAS阻害剤市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界のKRAS阻害剤市場の生産能力拡大
  • 世界のKRAS阻害剤市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• Amgen
• Boehringer Ingelheim
• BridgeBio Pharma
• Erasca
• Innovent Biologics
• Incyte
• Mirati Therapeutics
• Novartis
• Jemincare
• Cardiff Oncology

KRAS Inhibitors Trends and Forecast

The future of the global KRAS inhibitors market looks promising with opportunities in the clinic laboratory, cancer diagnostic center, hospital, cancer research institute, and academic institution markets. The global KRAS inhibitors market is expected to grow with a CAGR of 32.5% from 2024 to 2030. The major drivers for this market are increasing prevalence of KRAS mutations in various types of cancer, surge in number of ongoing clinical trials, and growing investments in precision medicine and personalized cancer treatment.

A more than 150-page report is developed to help in your business decisions.

KRAS Inhibitors by Segment

The study includes a forecast for the global KRAS inhibitors by cancer type, end use, and region.

KRAS Inhibitors Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

• Lung Cancer
• Pancreatic Cancer
• Colorectal Cancer
• Others

KRAS Inhibitors Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Clinic Laboratories
• Cancer Diagnostic Centers
• Hospitals
• Cancer Research Institutes
• Academic Institutions
• Others

KRAS Inhibitors Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of KRAS Inhibitors Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies KRAS inhibitors companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the KRAS inhibitors companies profiled in this report include-

• Amgen
• Boehringer Ingelheim
• Bridgebio Pharma
• Erasca
• Innovent Biologics
• Incyte
• Mirati Therapeutics
• Novartis
• Jemincare
• Cardiff Oncology

KRAS Inhibitors Market Insights

Lucintel forecasts that lung cancer is expected to witness highest growth over the forecast period due to surge in prevalence of KRW mutations in lung cancer patients and increasing focus towards research for lung cancer treatments.

Within this market, cancer research institutes will remain the largest segment due to the rising number of clinical research along with growing partnerships among research institutes and biotech companies.

North America will remain the largest region over the forecast period due to the high prevalence of cancer and presence of major players in the region.

Features of the Global KRAS Inhibitors Market

Market Size Estimates: KRAS inhibitors market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: KRAS inhibitors market size by cancer type, end use, and region in terms of value ($B).

Regional Analysis: KRAS inhibitors market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer types, end uses, and regions for the KRAS inhibitors market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the KRAS inhibitors market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for KRAS inhibitors market?

Answer: The global KRAS inhibitors market is expected to grow with a CAGR of 32.5% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the KRAS inhibitors market?

Answer: The major drivers for this market are increasing prevalence of KRAS mutations in various types of cancer, surge in number of ongoing clinical trials, and growing investments in precision medicine and personalized cancer treatment.

Q3. What are the major segments for KRAS inhibitors market?

Answer: The future of the global KRAS inhibitors market looks promising with opportunities in the clinic laboratory, cancer diagnostic center, hospital, cancer research institute, and academic institution markets.

Q4. Who are the key KRAS inhibitors market companies?

Answer: Some of the key KRAS inhibitors companies are as follows:

• Amgen
• Boehringer Ingelheim
• Bridgebio Pharma
• Erasca
• Innovent Biologics
• Incyte
• Mirati Therapeutics
• Novartis
• Jemincare
• Cardiff Oncology

Q5. Which KRAS inhibitors market segment will be the largest in future?

Answer: Lucintel forecasts that lung cancer is expected to witness highest growth over the forecast period due to surge in prevalence of KRW mutations in lung cancer patients and increasing focus towards research for lung cancer treatments.

Q6. In KRAS inhibitors market, which region is expected to be the largest in next 5 years?

Answer:North America will remain the largest region over the forecast period due to the high prevalence of cancer and presence of major players in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the KRAS inhibitors market by cancer type (lung cancer, pancreatic cancer, colorectal cancer, and others), end use (clinic laboratories, cancer diagnostic centers, hospitals, cancer research institutes, academic institutions, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global KRAS Inhibitors Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global KRAS Inhibitors Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global KRAS Inhibitors Market by Cancer Type
  • 3.3.1: Lung Cancer
  • 3.3.2: Pancreatic Cancer
  • 3.3.3: Colorectal Cancer
  • 3.3.4: Others
• 3.4: Global KRAS Inhibitors Market by End Use
  • 3.4.1: Clinic Laboratories
  • 3.4.2: Cancer Diagnostic Centers
  • 3.4.3: Hospitals
  • 3.4.4: Cancer Research Institutes
  • 3.4.5: Academic Institutions
  • 3.4.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global KRAS Inhibitors Market by Region
• 4.2: North American KRAS Inhibitors Market
  • 4.2.2: North American KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
• 4.3: European KRAS Inhibitors Market
  • 4.3.1: European KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
  • 4.3.2: European KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
• 4.4: APAC KRAS Inhibitors Market
  • 4.4.1: APAC KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
  • 4.4.2: APAC KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
• 4.5: ROW KRAS Inhibitors Market
  • 4.5.1: ROW KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
  • 4.5.2: ROW KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global KRAS Inhibitors Market by Cancer Type
  • 6.1.2: Growth Opportunities for the Global KRAS Inhibitors Market by End Use
  • 6.1.3: Growth Opportunities for the Global KRAS Inhibitors Market by Region
• 6.2: Emerging Trends in the Global KRAS Inhibitors Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global KRAS Inhibitors Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global KRAS Inhibitors Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Amgen
• 7.2: Boehringer Ingelheim
• 7.3: BridgeBio Pharma
• 7.4: Erasca
• 7.5: Innovent Biologics
• 7.6: Incyte
• 7.7: Mirati Therapeutics
• 7.8: Novartis
• 7.9: Jemincare
• 7.10: Cardiff Oncology